GFAP and Alzheimer disease: We therefore aimed to develop and validate prediction models utilizing blood-based biomarkers pTau181, pTau217, Aβ42/40, GFAP and/or NfL, for individualized determination of any-cause dementia risk as well as specifically Alzheimer’s dementia risk in a memory clinic sample of patients with MCI, or SCD.